

## Reduction in susceptibility for variants and COVID-19 monoclonal antibodies comparison chart

Pseudotyped Virus-Like Particles and Authentic SARS-CoV-2 Neutralization Data

Pseudotyped Virus-Like Particles Neutralization Data

Authentic SARS-CoV-2 Neutralization Data

<u>Lineage with Spike Protein Substitution</u>	<u>WHO Nomenclature</u>	<u>Origin</u>	<u>Key Substitutions Tested</u>	<u>Bebtelovimab</u>	<u>Sotrovimab</u>	<u>Tixagevimab/ Cilgavimab</u>	<u>Casirivimab/ Imdevimab</u>	<u>Bamlanivimab/ Etesevimab</u>
B.1.117	Alpha	UK	N501Y	No Change	No change	0.5 to 5.2	No change	No change
B.1.351	Beta	S. Africa	K417N+ E484K+ N501Y	No change	No change	No change	No change	Unlikely active >324
P.1	Gamma	Brazil	K417T+ E484K+ N501Y	No change NR	No change	No change	No change	Unlikely active NR
B.1.617	Delta	India	L452R+ E484Q	No change	NR No change	No change	No change	Active for AY.3, not AY.1 or AY.2 No change AY.3
B.1.427/ B.1.429	Epsilon	California	L452R	No change	No Change NR	No change	No Change NR	9 11
B.1.525	Eta	Multiple Countries	E484K	NR	NR	No change Unknown	NR NR	NR
B.1.526	Iota	New York	E484K	No change	No Change NR	No change	No Change NR	30 11
B.617.1	Kappa	India	L452R+ E484Q	No change NR	No Change NR	No change	No change	6 NR
C.37	Lambda	Peru	L452Q+ F490S	No change NR	No Change NR	No change Unknown	NR	No change NR
B.1.621	Mu	Colombia	R346K+ E484K+ N501Y	5.3 NR	No Change NR	7.5 Unknown	No Change NR	Unlikely active NR
B.1.1.529/BA.1	Omicron	S. Africa	G339D+ S371L+ S373P+ S375F+ K417N + N440K+ G446S + S477N+ T478K + E484A+ Q493R + G496S+ Q498R + N501Y+ Y505H	No change NR	No Change NR	132-183 12-30	Unlikely active NR	Unlikely active NR
B.1.1.529/BA.1.1	Omicron	S. Africa	G339D+ R346K+ S371L+ S373P+ S375F+ K417N+ N440K+ G446S+ S477N+ T478K+ E484A+Q493R+ G496S+ Q498R+ N501Y+ Y505H	No change NR	No Change NR	424 176	NR	NR
B.1.1.529/BA.2	Omicron	S. Africa	G339D+ S371F+ S373P+ S375F+ T376A+ D405N+ R408S+ K417N+ N440K+ S477N+ T478K+ E484A+ Q493R+ Q498R+ N501Y+ Y505H	No change NR	16 NR	No Change 5.4	NR	NR